Merrimack Pharma (MACK) Misses Q1 EPS by 12c, Miss on Revenues

Merrimack Pharma (NASDAQ: MACK) reported Q1 EPS of ($0.23), $0.12 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $21.6 million versus the consensus estimate of $24.12 million.

For earnings history and earnings-related data on Merrimack Pharma (MACK) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• SanDisk upgraded at JPMorgan after investor day; shares climb